CMRX Chimerix
- 3.460
- +0.240+7.45%
- 3.529
- +0.069+1.99%
Chimerix News
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
TD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $5
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Chimerix Analyst Ratings
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $5
Chimerix's Positive Phase 3 Trial Progress and Strong Financial Position Justify 'Buy' Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Capital One Financial Maintains Chimerix(CMRX.US) With Buy Rating, Cuts Target Price to $6
Chimerix Analyst Ratings
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
No Data
